Now available: Small, cost-effective liquid biopsy NGS assay
AmoyDx® HRR Liquid NGS Panel: Detection of mutations in 24 genes
The AmoyDx® HRR Liquid NGS Panel (RUO) is an NGS assay for the qualitative detection of mutations (SNVs, InDels) in 20 HRR genes as well as PTEN, AKT1, PIK3CA and AR on cfDNA from blood plasma. The small, cost-effective panel covers the most important HRR genes including all genes mentioned in the S3 guideline “Prostate cancer”, version 7.0, May 2024 in the context of a PARPi therapy [1].
The library is prepared using the hybrid capture method (ddCAP technology) over two days and the sequence data is analyzed locally by the AmoyDx® NGS Data Analysis System (ANDAS).
For more information, please click here.
Alternatively, you can contact us directly at molpath@zytomed-systems.de
Stay tuned for more liquid biopsy products coming soon.
[1] S3-Leitlinie Prostatakarzinom Version 7.0 – Mai 2024 AWMF-Registernummer: 043-022OL
Further topics
Introducing: The AmoyDx® HANDLE Melanoma NGS Panel
The AmoyDx® HANDLE Melanoma NGS Panel is a Next-Generation Sequencing-based assay for the qualitative detection of SNVs and InDels in nine key melanoma genes.
PRAME (EPR20330) in dermatopathology
PRAME (PReferentially-expressed Antigen in MElanoma) was first described in a paper by Ikeda et al., through analysis of the specificity of tumor-reactive T-cell clones derived from a patient with metastatic cutaneous melanoma. [1, 2]
